January 2026 in “Journal of Dermatology Research and Therapy” This case series examines the management of recalcitrant Alopecia Areata (AA) in five Black pediatric patients using a combination therapy approach. The treatment included topical janus kinase inhibitors (JAKi), oral fexofenadine, and vitamin D supplementation, with additional therapies like oral upadacitinib, platelet-rich plasma, red light therapy, and excimer UVB phototherapy in some cases. All patients experienced significant hair regrowth and reduced disease severity, achieving Alopecia Areata Investigator Global Assessment scores of ≤ 1, indicating minimal or no disease activity. The study supports the efficacy of JAK inhibitors for pediatric AA and suggests that combination therapy can effectively reduce disease progression and prevent relapse, with minimal adverse effects.
July 2014 in “Journal of the Dermatology Nurses' Association” The document concluded with a call for article submissions for the 2014 Writing Awards.
2 citations
,
January 2012 in “Journal of Clinical & Experimental Dermatology Research” Fexofenadine reduces discomfort but doesn't significantly improve hair regrowth in Alopecia Areata treatment.
November 2025 in “Journal of Investigative Dermatology” Combination therapy, including JAK inhibitors, effectively regrows hair and reduces severity in Black children with stubborn Alopecia Areata.
55 citations
,
July 2013 in “Dermatologic therapy” Some dermatological medications can impair male fertility, so consult a doctor before trying to conceive.